Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Regien G Schoemaker

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
American Journal of Physiology. Heart and Circulatory Physiology|May 9, 2006
Right and left ventricular function after chronic pulmonary artery banding in rats assessed with biventricular pressure-volume loopsMatthijs J Faber, Michiel Dalinghaus, Inge M Lankhuizen, et al.
Journal of Cardiovascular Pharmacology|September 30, 2004
Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusionErik Lipsic, Peter van der Meer, Robert H Henning, et al.
European Journal of Heart Failure|December 14, 2007
Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocritErik Lipsic, B Daan Westenbrink, Peter van der Meer, et al.
Cardiovascular Research|February 9, 2010
Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failureB Daan Westenbrink, Willem-Peter T Ruifrok, Adriaan A Voors, et al.
Journal of the American College of Cardiology|July 5, 2005
Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarctionPeter van der Meer, Erik Lipsic, Robert H Henning, et al.
Circulation|September 21, 2005
Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failurePeter van der Meer, Erik Lipsic, B Daan Westenbrink, et al.
Brain, Behavior, and Immunity|March 26, 2016
Depression and markers of inflammation as predictors of all-cause mortality in heart failurePaula M C Mommersteeg, Regien G Schoemaker, Petrus J W Naudé, et al.
Circulation. Heart Failure|January 28, 2010
Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarctionYong Wang, Cheng Qian, Anton J M Roks, et al.
Cardiovascular Drugs and Therapy|March 11, 2008
Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemiaB Daan Westenbrink, Hisko Oeseburg, Lennaert Kleijn, et al.
European Heart Journal|June 20, 2007
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularizationB Daan Westenbrink, Erik Lipsic, Peter van der Meer, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
American Journal of Physiology. Heart and Circulatory Physiology|May 9, 2006
Right and left ventricular function after chronic pulmonary artery banding in rats assessed with biventricular pressure-volume loopsMatthijs J Faber, Michiel Dalinghaus, Inge M Lankhuizen, et al.
Journal of Cardiovascular Pharmacology|September 30, 2004
Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusionErik Lipsic, Peter van der Meer, Robert H Henning, et al.
European Journal of Heart Failure|December 14, 2007
Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocritErik Lipsic, B Daan Westenbrink, Peter van der Meer, et al.
Cardiovascular Research|February 9, 2010
Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failureB Daan Westenbrink, Willem-Peter T Ruifrok, Adriaan A Voors, et al.
Journal of the American College of Cardiology|July 5, 2005
Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarctionPeter van der Meer, Erik Lipsic, Robert H Henning, et al.
Circulation|September 21, 2005
Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failurePeter van der Meer, Erik Lipsic, B Daan Westenbrink, et al.
Brain, Behavior, and Immunity|March 26, 2016
Depression and markers of inflammation as predictors of all-cause mortality in heart failurePaula M C Mommersteeg, Regien G Schoemaker, Petrus J W Naudé, et al.
Circulation. Heart Failure|January 28, 2010
Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarctionYong Wang, Cheng Qian, Anton J M Roks, et al.
Cardiovascular Drugs and Therapy|March 11, 2008
Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemiaB Daan Westenbrink, Hisko Oeseburg, Lennaert Kleijn, et al.
European Heart Journal|June 20, 2007
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularizationB Daan Westenbrink, Erik Lipsic, Peter van der Meer, et al.
Pageof 7